Update on melatonin receptors: IUPHAR Review 20

British Journal of Pharmacology

Volumn , Issue , 2016, Pages 2702-2725

  Jockers, Ralf ^a,b   Delagrange, Philippe ^c   Dubocovich, Margarita L ^d   Markus, Regina P ^e   Renault, Nicolas ^f   Tosini, Gianluca ^g   Cecon, Erika ^a,b   Zlotos, Darius P ^h  

^a INSTITUT COCHIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITÉ DE LILLE   (France)

^g MOREHOUSE SCHOOL OF MEDICINE   (United States)

^h GERMAN UNIVERSITY IN CAIRO   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

2 IODOMELATONIN; 2 METHOXY ALPHA, BETA DIDEHYDRO AGOMELATINE; 5 HEAT; 5 METHOXYLUZINDOLE; 6 CHLOROMELATONIN; 6 HYDROXYMELATONIN; AGOMELATINE; BOMPPA; CIFEA; DIMER; EFPPEA; GR 128107; GR 196429; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR; MELATONIN RECEPTOR AGONIST; RADIOLIGAND; RAMELTEON; RECEPTOR BLOCKING AGENT; RECEPTOR LIGAND; S 22153; S 24014; S 24773; SCAVENGER; TASIMELTEON; TIK 301; UCM 1014; UCM 793; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ANTIOXIDANT ACTIVITY; BINDING AFFINITY; BRAIN DEVELOPMENT; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG STRUCTURE; GENETIC VARIABILITY; IMMUNE SYSTEM; INNATE IMMUNITY; MISSENSE MUTATION; MTNR1A GENE; MTNR1B GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORGANIZATION; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; STRUCTURE ANALYSIS;

EID: 84982890576     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13536     Document Type: Review

References (208)

1. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE et al. (2012). An integrated map of genetic variation from 1,092 human genomes. Nature 491: 56–65.
2. Adachi A, Natesan AK, Whitfield-Rucker MG, Weigum SE, Cassone VM (2002). Functional melatonin receptors and metabolic coupling in cultured chick astrocytes. Glia 39: 268–278.
3. Adamah-Biassi EB, Stepien I, Hudson RL, Dubocovich ML (2013). Automated video analysis system reveals distinct diurnal behaviors in C57BL/6 and C3H/HeN mice. Behav Brain Res 243: 306–312.
4. Adi N, Mash DC, Ali Y, Singer C, Shehadeh L, Papapetropoulos S (2010). Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Med Sci Monit 16: BR61–BR67.
5. Alarma-Estrany P, Crooke A, Pintor J (2009). 5-MCA-NAT does not act through NQO2 to reduce intraocular pressure in New-Zealand white rabbit. J Pineal Res 47: 201–209.
6. Alcantara-Contreras S, Baba K, Tosini G (2011). Removal of melatonin receptor type 1 increases intraocular pressure and retinal ganglion cells death in the mouse. Neurosci Lett 494: 61–64.
7. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: G Protein-Coupled Receptors. Br J Pharmacol 172: 5744–5869.
8. Alexander SPH, Catterall WA, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels. Br J Pharmacol 172: 5904–5941.
9. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110–6202.
10. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015d). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
11. Andersson EA, Holst B, Sparso T, Grarup N, Banasik K, Holmkvist J et al. (2010). MTNR1B G24E variant associates with BMI and fasting plasma glucose in the general population in studies of 22,142 Europeans. Diabetes 59: 1539–1548.
12. Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, Le Gall A, Amosse C et al. (2003). New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 367: 553–561.
13. Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M et al. (2002). Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem 277: 21522–21528.
14. Ayoub MA, Levoye A, Delagrange P, Jockers R (2004). Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers. Mol Pharmacol 66: 312–321.
15. Baba K, Benleulmi-Chaachoua A, Journe AS, Kamal M, Guillaume JL, Dussaud S et al. (2013). Heteromeric MT1/MT2 melatonin receptors modulate photoreceptor function. Sci Signal 6: ra89.
16. Baba K, Davidson AJ, Tosini G (2015). Melatonin Entrains PER2::LUC Bioluminescence Circadian Rhythm in the Mouse Cornea. Invest Ophthalmol Vis Sci 56: 4753–4758.
17. Baba K, Pozdeyev N, Mazzoni F, Contreras-Alcantara S, Liu C, Kasamatsu M et al. (2009). Melatonin modulates visual function and cell viability in the mouse retina via the MT1 melatonin receptor. Proc Natl Acad Sci U S A 106: 15043–15048.
18. Benleulmi-Chaachoua A, Chen L, Sokolina K, Wong V, Jurisica I, Emerit MB et al. (2016). Protein interactome mining defines melatonin MT1 receptors as integral component of presynaptic protein complexes of neurons. J Pineal Res 60: 95–108.
19. Bonnefond A, Clement N, Fawcett K, Yengo L, Vaillant E, Guillaume JL et al. (2012). Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet 44: 297–301.
20. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M et al. (2009). A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 41: 89–94.
21. Browning C, Beresford I, Fraser N, Giles H (2000). Pharmacological characterization of human recombinant melatonin mt(1) and MT2 receptors. Br J Pharmacol 129: 877–886.
22. Cardinali DP, Furio AM, Brusco LI (2010). Clinical aspects of melatonin intervention in Alzheimer's disease progression. Curr Neuropharmacol 8: 218–227.
23. Carrillo VA, Calvo JR, Abreu P, Lardone PJ, Garcia MS, Reiter RJ et al. (2004). Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 18: 537–539.
24. Carrillo-Vico A, Lardone PJ, Alvarez-Sanchez N, Rodriguez-Rodriguez A, Guerrero JM (2013). Melatonin: buffering the immune system. Int J Mol Sci 14: 8638–8683.
25. Cecon E, Chen M, Marcola M, Fernandes PA, Jockers R, Markus RP (2015). Amyloid beta peptide directly impairs pineal gland melatonin synthesis and melatonin receptor signaling through the ERK pathway. FASEB J 29: 2566–2582.
26. Cernysiov V, Mauricas M, Girkontaite I (2015). Melatonin inhibits granulocyte adhesion to ICAM via MT3/QR2 and MT2 receptors. Int Immunol 27: 599–608.
27. Chan KH, Hu Y, Ho MK, Wong YH (2013). Characterization of substituted phenylpropylamides as highly selective agonists at the melatonin MT2 receptor. Curr Med Chem 20: 289–300.
28. Chaste P, Clement N, Botros HG, Guillaume JL, Konyukh M, Pagan C et al. (2011). Genetic variations of the melatonin pathway in patients with attention-deficit and hyperactivity disorders. J Pineal Res 51: 394–399.
29. Chaste P, Clement N, Mercati O, Guillaume JL, Delorme R, Botros HG et al. (2010). Identification of pathway-biased and deleterious melatonin receptor mutants in autism spectrum disorders and in the general population. PLoS One 5: e11495.
30. Chen X, Li X, Du Z, Shi W, Yao Y, Wang C et al. (2014). Melatonin promotes the acquisition of neural identity through extracellular-signal-regulated kinases1/2activation. J Pineal Res 57: 168–176.
31. Chugunov AO, Farce A, Chavatte P, Efremov RG (2006). Differences in binding sites of two melatonin receptors help to explain their selectivity to some melatonin analogs: a molecular modeling study. J Biomol Struct Dyn 24: 91–107.
32. Clough SJ, Hutchinson AJ, Hudson RL, Dubocovich ML (2014). Genetic deletion of the MT1 or MT2 melatonin receptors abrogates methamphetamine-induced reward in C3H/HeN mice. Physiol Behav 132: 79–86.
33. Comai S, Ochoa-Sanchez R, Gobbi G (2013). Sleep–wake characterization of double MT(1)/MT(2) receptor knockout mice and comparison with MT(1) and MT(2) receptor knockout mice. Behav Brain Res 243: 231–238.
34. Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M, Maestroni JM (2000). Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 28: 193–202.
35. Contreras-Alcantara S, Baba K, Tosini G (2010). Removal of melatonin receptor type 1 induces insulin resistance in the mouse. Obesity (Silver Spring) 18: 1861–1863.
36. Conway S, Mowat ES, Drew JE, Barrett P, Delagrange P, Morgan PJ (2001). Serine residues 110 and 114 are required for agonist binding but not antagonist binding to the melatonin MT(1) receptor. Biochem Biophys Res Commun 282: 1229–1236.
37. Daulat AM, Maurice P, Froment C, Guillaume JL, Broussard C, Monsarrat B et al. (2007). Purification and identification of G protein-coupled receptor protein complexes under native conditions. Mol Cell Proteomics 6: 835–844.
38. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ (2010). Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 9: 628–642.
39. de la Fuente Revenga M, Fernandez-Saez N, Herrera-Arozamena C, Morales-Garcia JA, Alonso-Gil S, Perez-Castillo A et al. (2015). Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential. J Med Chem 58: 4998–5014.
40. Descamps-Francois C, Yous S, Chavatte P, Audinot V, Bonnaud A, Boutin JA et al. (2003). Design and Synthesis of Naphthalenic Dimers as Selective MT1 Melatoninergic Ligands. J Med Chem 46: 1127–1129.
41. Dominguez-Alonso A, Valdes-Tovar M, Solis-Chagoyan H, Benitez-King G (2015). Melatonin stimulates dendrite formation and complexity in the hilar zone of the rat hippocampus: participation of the Ca++/Calmodulin complex. Int J Mol Sci 16: 1907–1927.
42. Dror RO, Green HF, Valant C, Borhani DW, Valcourt JR, Pan AC et al. (2013). Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 503: 295–299.
43. Dubocovich ML (1985). Characterization of a retinal melatonin receptor. J Pharmacol Exp Ther 234: 395–401.
44. Dubocovich ML (1988). Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther 246: 902–910.
45. Dubocovich ML (1983). Melatonin is a potent modulator of dopamine release in the retina. Nature 306: 782–784.
46. Dubocovich ML (1995). Melatonin receptors: Are there multiple subtypes? Trends Pharmacol Sci 16: 50–56.
47. Dubocovich ML (2007). Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med 8 (Suppl 3): 34–42.
48. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J (2010). International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 62: 343–380.
49. Dubocovich ML, Hudson RL, Sumaya IC, Masana MI, Manna E (2005). Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the C57BL/6 mouse. J Pineal Res 39: 113–120.
50. Dubocovich ML, Masana MI, Iacob S, Sauri DM (1997). Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol 355: 365–375.
51. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI (2003). Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 8: d1093–d1108.
52. Dubocovich ML, Takahashi JS (1987). Use of 2-[125I]iodomelatonin to characterize melatonin binding sites in chicken retina. Proc Natl Acad Sci U S A 84: 3916–3920.
53. Dubocovich ML, Yun K, AlGhoul WM, Benloucif S, Masana MI (1998). Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J 12: 1211–1220.
54. Ebisawa T, Kajimura N, Uchiyama M, Katoh M, Sekimoto M, Watanabe T et al. (1999). Alleic variants of human melatonin 1a receptor: Function and prevalence in subjects with circadian rhythm sleep disorders. Biochem Biophys Res Commun 262: 832–837.
55. Escribano BM, Colin-Gonzalez AL, Santamaria A, Tunez I (2014). The role of melatonin in multiple sclerosis, Huntington's disease and cerebral ischemia. CNS Neurol Disord Drug Targets 13: 1096–1119.
56. Ettaoussi M, Sabaouni A, Rami M, Boutin JA, Delagrange P, Renard P et al. (2012). Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). Eur J Med Chem 49: 310–323.
57. Evely KM, Hudson RL, Dubocovich ML, Haj-Dahmane S (2016). Melatonin receptor activation increases glutamatergic synaptic transmission in the rat medial lateral habenula. Synapse 70: 181–186.
58. Fang JM, Dubocovich ML (1990). Activation of melatonin receptor sites retarded the depletion of norepinephrine following inhibition of synthesis in the C3H/HeN mouse hypothalamus. J Neurochem 55: 76–82.
59. Farce A, Chugunov AO, Loge C, Sabaouni A, Yous S, Dilly S et al. (2008). Homology modeling of MT1 and MT2 receptors. Eur J Med Chem 43: 1926–1944.
60. Farez MF, Mascanfroni ID, Mendez-Huergo SP, Yeste A, Murugaiyan G, Garo LP et al. (2015). Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. Cell 162: 1338–1352.
61. Faust R, Garratt PJ, Jones R, Yeh LK, Tsotinis A, Panoussopoulou M et al. (2000). Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles. J Med Chem 43: 1050–1061.
62. Ferre S, Casado V, Devi LA, Filizola M, Jockers R, Lohse MJ et al. (2014). G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev 66: 413–434.
63. Fisher SP, Sugden D (2009). Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat. Neurosci Lett 457: 93–96.
64. Gerdin MJ, Masana MI, Rivera-Bermudez MA, Hudson RL, Earnest DJ, Gillette MU et al. (2004). Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J 18: 1646–1656.
65. Gerdin MJ, Mseeh F, Dubocovich ML (2003). Mutagenesis studies of the human MT2 melatonin receptor. Biochem Pharmacol 66: 315–320.
66. Gianesini C, Hiragaki S, Laurent V, Hicks D, Tosini G (2016). Cone Viability Is Affected by Disruption of Melatonin Receptors Signaling. Invest Ophthalmol Vis Sci 57: 94–104.
67. Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P et al. (2001). Effects of melatonin treatment in septic newborns. Pediatr Res 50: 756–760.
68. Green NH, Jackson CR, Iwamoto H, Tackenberg MC, McMahon DG (2015). Photoperiod programs dorsal raphe serotonergic neurons and affective behaviors. Curr Biol 25: 1389–1394.
69. Heckman D, Attia MI, Behnam MAM, Mohsen AMY, Markl C, Julius J et al. (2011). 2-[(1,3-Dihydro-2H-isoindol-2yl)methyl]-melatonin- a novel MT2-selective melatonin receptor antagonist. Med Chem Commun 2: 991–994.
70. Hevia D, Gonzalez-Menendez P, Quiros-Gonzalez I, Miar A, Rodriguez-Garcia A, Tan DX et al. (2015). Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer. J Pineal Res 58: 234–250.
71. Hotta CT, Gazarini ML, Beraldo FH, Varotti FP, Lopes C, Markus RP et al. (2000). Calcium-dependent modulation by melatonin of the circadian rhythm in malarial parasites. Nat Cell Biol 2: 466–468.
72. Hu Y, Ho MKC, Chan KH, New DC, Wong YH (2010). Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT2-selective melatonin ligands. Bioorg Med Chem Lett 20: 2582–2585.
73. Hu Y, Zhu J, Chan KH, Wong YH (2013). Development of substituted N-[3-(3-methoxylphenyl)propyl] amides as MT(2)-selective melatonin agonists: improving metabolic stability. Bioorg Med Chem 21: 547–552.
74. Hunt AE, AlGhoul WM, Gillette MU, Dubocovich ML (2001). Activation of MT2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol 280: C110–C118.
75. Hutchinson AJ, Hudson RL, Dubocovich ML (2012). Genetic deletion of MT(1) and MT(2) melatonin receptors differentially abrogates the development and expression of methamphetamine-induced locomotor sensitization during the day and the night in C3H/HeN mice. J Pineal Res 53: 399–409.
76. Jilg A, Moek J, Weaver DR, Korf HW, Stehle JH, von Gall C (2005). Rhythms in clock proteins in the mouse pars tuberalis depend on MT1 melatonin receptor signalling. Eur J Neurosci 22: 2845–2854.
77. Jin XW, von Gall C, Pieschl RL, Gribkoff VK, Stehle JH, Reppert SM et al. (2003). Targeted disruption of the mouse Mel(1b) melatonin receptor. Mol Cell Biol 23: 1054–1060.
78. Jockers R, Maurice P, Boutin JA, Delagrange P (2008). Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol 154: 1182–1195.
79. Johnston JD, Skene DJ (2015). 60 YEARS OF NEUROENDOCRINOLOGY: Regulation of mammalian neuroendocrine physiology and rhythms by melatonin. J Endocrinol 226: T187–T198.
80. Johnston JM, Filizola M (2014). Beyond standard molecular dynamics: investigating the molecular mechanisms of G protein-coupled receptors with enhanced molecular dynamics methods. Adv Exp Med Biol 796: 95–125.
81. Joshi N, Biswas J, Nath C, Singh S (2015). Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology. Mol Neurobiol 52: 330–340.
82. Journe AS, Habib SAM, Dodda BR, Morcos MNF, Sadek MS, Tadros SAA et al. (2014). N1-linked melatonin dimers as bivalent ligands targeting dimeric melatonin receptors. Med Chem Commun 5: 792–796.
83. Kamal M, Gbahou F, Guillaume JL, Daulat AM, Benleulmi-Chaachoua A, Luka M et al. (2015). Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers. J Biol Chem 290: 11537–11546.
84. Kang Y, Zhou XE, Gao X, He Y, Liu W, Ishchenko A et al. (2015). Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature 523: 561–567.
85. Karamitri A, Jockers R (2014). Exon Sequencing of G Protein-Coupled Receptor Genes and Perspectives for Disease Treatment. In: Stefens CW (ed). Methods in Pharmacology and Toxicology series, G Protein-Coupled Receptor Genetics: Research and Methods in the Post-Genomic Era. Springer Science: New York, pp. 313–332.
86. Karamitri A, Renault N, Clement N, Guillaume JL, Jockers R (2013). Minireview: Toward the Establishment of a Link between Melatonin and Glucose Homeostasis: Association of Melatonin MT2 Receptor Variants with Type 2 Diabetes. Mol Endocrinol 27: 1217–1233.
87. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S et al. (2005). Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48: 301–310.
88. Koike T, Hoashi Y, Takai T, Nakayama M, Yukuhiro N, Ishikawa T et al. (2011). 1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT(2)-selective agonists. J Med Chem 54: 3436–3444.
89. Kokkola T, Foord SM, Watson MA, Vakkuri O, Laitinen JT (2003). Important amino acids for the function of the human MT1 melatonin receptor. Biochem Pharmacol 65: 1463–1471.
90. Kong X, Li X, Cai Z, Yang N, Liu Y, Shu J et al. (2008). Melatonin regulates the viability and differentiation of rat midbrain neural stem cells. Cell Mol Neurobiol 28: 569–579.
91. Krause DN, Siuciak JA, Dubocovich ML (1992). Optic nerve transection decreases 2-[125I]iodomelatonin binding in the chick optic tectum. Brain Res 590: 325–328.
92. Krause DN, Siuciak JA, Dubocovich ML (1994). Unilateral optic nerve transection decreases 2-[125I]-iodomelatonin binding in retinorecipient areas and visual pathways of chick brain. Brain Res 654: 63–74.
93. Lahiri S, Haldar C (2009). Response of melatonin receptor MT1 in spleen of a tropical Indian rodent, Funambulus pennanti, to natural solar insolation and different photoperiodic conditions. Chronobiol Int 26: 1559–1574.
94. Landolt HP, Wehrle R (2009). Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci 29: 1795–1809.
95. Laranjeira-Silva MF, Zampieri RA, Muxel SM, Floeter-Winter LM, Markus RP (2015). Melatonin attenuates Leishmania (L.) amazonensis infection by modulating arginine metabolism. J Pineal Res 59: 478–487.
96. Lardone PJ, Carrillo-Vico A, Naranjo MC, De Felipe B, Vallejo A, Karasek M et al. (2006). Melatonin synthesized by Jurkat human leukemic T cell line is implicated in IL-2 production. J Cell Physiol 206: 273–279.
97. Lardone PJ, Rubio A, Cerrillo I, Gomez-Corvera A, Carrillo-Vico A, Sanchez-Hidalgo M et al. (2010). Blocking of melatonin synthesis and MT(1) receptor impairs the activation of Jurkat T cells. Cell Mol Life Sci 67: 3163–3172.
98. Larson J, Jessen RE, Uz T, Arslan AD, Kurtuncu M, Imbesi M et al. (2006). Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. Neurosci Lett 393: 23–26.
99. Lavedan C, Forsberg M, Gentile AJ (2015). Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology 91: 142–147.
100. Legros C, Brasseur C, Delagrange P, Ducrot P, Nosjean O, Boutin JA (2016). Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors. J Pharmacol Exp Ther 356: 681–692.
101. Legros C, Chesneau D, Boutin JA, Barc C, Malpaux B (2014). Melatonin from cerebrospinal fluid but not from blood reaches sheep cerebral tissues under physiological conditions. J Neuroendocrinol 26: 151–163.
102. Legros C, Matthey U, Grelak T, Pedragona-Moreau S, Hassler W, Yous S et al. (2013). New Radioligands for Describing the Molecular Pharmacology of MT1 and MT2 Melatonin Receptors. Int J Mol Sci 14: 8948–8962.
103. Levoye A, Dam J, Ayoub MA, Guillaume JL, Couturier C, Delagrange P et al. (2006a). The orphan GPR50 receptor specifically inhibits MT(1) melatonin receptor function through heterodimerization. EMBO J 25: 3012–3023.
104. Levoye A, Dam J, Ayoub MA, Guillaume JL, Jockers R (2006b). Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers. EMBO Rep 7: 1094–1098.
105. Liao S, Williams-Ashman HG (1961). Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide. Biochem Biophys Res Commun 4: 208–213.
106. Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK et al. (1997). Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19: 91–102.
107. Liu D, Wei N, Man HY, Lu Y, Zhu LQ, Wang JZ (2015). The MT2 receptor stimulates axonogenesis and enhances synaptic transmission by activating Akt signaling. Cell Death Differ 22: 583–596.
108. Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML (2016). MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol 56: 361–383.
109. Lotufo CM, Lopes C, Dubocovich ML, Farsky SH, Markus RP (2001). Melatonin and N-acetylserotonin inhibit leukocyte rolling and adhesion to rat microcirculation. Eur J Pharmacol 430: 351–357.
110. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spegel P et al. (2009). Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 41: 82–88.
111. Maestroni G (1993). Th immunoneuroendocrine role of melatonin. J Pineal Res 14: 1–10.
112. Markl C, Clafshenkel WP, Attia MI, Sethi S, Witt-Enderby PA, Zlotos DP (2011). N-Acetyl-5-arylalkoxytryptamine analogs: probing the melatonin receptors for MT(1) -selectivity. Arch Pharm (Weinheim) 344: 666–674.
113. Markus RP, Cecon E, Pires-Lapa MA (2013). Immune-Pineal Axis: Nuclear Factor Œ∫B (NF-kB) Mediates the Shift in the Melatonin Source from Pinealocytes to Immune Competent Cells. Int J Mol Sci 14: 10979–10997 %! Immune-Pineal Axis: Nuclear Factor Œ∫B (NF-kB) Mediates the Shift in the Melatonin Source from Pinealocytes to Immune Competent Cells %@ 11422-10067.
114. Maurice P, Daulat AM, Broussard C, Mozo J, Clary G, Hotellier F et al. (2008). A generic approach for the purification of signaling complexes that specifically interact with the carboxy-terminal domain of G protein-coupled receptors. Mol Cell Proteomics 7: 1556–1569.
115. Maurice P, Kamal M, Jockers R (2011). Asymmetry of GPCR oligomers supports their functional relevance. Trends Pharmacol Sci 32: 514–520.
116. Mazna P, Obsilova V, Jelinkova I, Balik A, Berka K, Sovova Z et al. (2004). Molecular modeling of human MT2 melatonin receptor: the role of Val204, Leu272 and Tyr298 in ligand binding. J Neurochem 91: 836–842.
117. McArthur A, Hunt A, Gillette M (1997). Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: Activation of protein kinase C at dusk and dawn. Endocrinology 138: 627–634.
118. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, Magalhaes MC, de Lourdes Seabra M, de Bruin VM (2007). Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol 254: 459–464.
119. Mesangeau C, Peres B, Descamps-Francois C, Chavatte P, Audinot V, Coumailleau S et al. (2010). Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands. Bioorg Med Chem 18: 3426–3436.
120. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V et al. (2003). The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306: 954–964.
121. Mini LJ, Wang-Weigand S, Zhang J (2007). Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother 5: 177–184.
122. Molinari EJ, North PC, Dubocovich ML (1996). 2-[I-125]iodo-5-methoxycarbonylamino-N-acetyltryptamine: A selective radioligand for the characterization of melatonin ML(2) binding sites. Eur J Pharmacol 301: 159–168.
123. Morellato L, Lefas-Le Gall M, Langlois M, Caignard DH, Renard P, Delagrange P et al. (2013). Synthesis of new N-(arylcyclopropyl)acetamides and N-(arylvinyl)acetamides as conformationally-restricted ligands for melatonin receptors. Bioorg Med Chem Lett 23: 430–434.
124. Muhlbauer E, Gross E, Labucay K, Wolgast S, Peschke E (2009). Loss of melatonin signalling and its impact on circadian rhythms in mouse organs regulating blood glucose. Eur J Pharmacol 606: 61–71.
125. Mulchahey JJ, Goldwater DR, Zemlan FP (2004). A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. Life Sci 75: 1843–1856.
126. Muxel SM, Laranjeira-Silva MF, de Carvalho Sousa CE, Floeter-Winter LM, Markus RP (2016). The RelA/cRel nuclear factor-kappaB (NF-kappaB) dimer, crucial for inflammation resolution, mediates the transcription of the key enzyme in melatonin synthesis in RAW 264.7 macrophages. J Pineal Res 60: 394–404.
127. Muxel SM, Pires-Lapa MA, Monteiro AW, Cecon E, Tamura EK, Floeter-Winter LM et al. (2012). NF-kappaB drives the synthesis of melatonin in RAW 264.7 macrophages by inducing the transcription of the arylalkylamine-N-acetyltransferase (AA-NAT) gene. PLoS One 7: e52010.
128. Naskar A, Prabhakar V, Singh R, Dutta D, Mohanakumar KP (2015). Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. J Pineal Res 58: 262–274.
129. Nelson MR, Wegmann D, Ehm MG, Kessner D, St Jean P, Verzilli C et al. (2012). An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science 337: 100–104.
130. Nonno R, Lucini V, Spadoni G, Pannacci M, Croce A, Esposti D et al. (2000). A new melatonin receptor ligand with mt(1)-agonist and MT2-antagonist properties. J Pineal Res 29: 234–240.
131. Nosjean O, Ferro M, Cogé F, Beauverger P, Henlin JM, Lefoulon F et al. (2000). Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 275: 31311–31317.
132. O'Neal-Moffitt G, Delic V, Bradshaw PC, Olcese J (2015). Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AbetaPP(swe)/PS1 mice. Mol Neurodegener 10: 27.
133. O'Neal-Moffitt G, Pilli J, Kumar SS, Olcese J (2014). Genetic deletion of MT1/MT2 melatonin receptors enhances murine cognitive and motor performance. Neuroscience 277: 506–521.
134. Ochoa-Sanchez R, Comai S, Lacoste B, Bambico FR, Dominguez-Lopez S, Spadoni G et al. (2011). Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci 31: 18439–18452.
135. Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, Shichida Y (2002). Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci U S A 99: 5982–5987.
136. Okada T, Sugihara M, Bondar AN, Elstner M, Entel P, Buss V (2004). The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J Mol Biol 342: 571–583.
137. Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ et al. (2009). Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 47: 82–96.
138. Ortiz GG, Pacheco-Moises FP, Gomez-Rodriguez VM, Gonzalez-Renovato ED, Torres-Sanchez ED, Ramirez-Anguiano AC (2013). Fish oil, melatonin and vitamin E attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Metab Brain Dis 28: 705–709.
139. Owino S, Contreras-Alcantara S, Baba K, Tosini G (2016). Melatonin Signaling Controls the Daily Rhythm in Blood Glucose Levels Independent of Peripheral Clocks. PLoS One 11: e0148214.
140. Pala D, Beuming T, Sherman W, Lodola A, Rivara S, Mor M (2013). Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. J Chem Inf Model 53: 821–835.
141. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA et al. (2000). Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289: 739–745.
142. Peng CX, Hu J, Liu D, Hong XP, Wu YY, Zhu LQ et al. (2013). Disease-modified glycogen synthase kinase-3beta intervention by melatonin arrests the pathology and memory deficits in an Alzheimer's animal model. Neurobiol Aging 34: 1555–1563.
143. Pfeffer M, Rauch A, Korf HW, von Gall C (2012). The endogenous melatonin (MT) signal facilitates reentrainment of the circadian system to light-induced phase advances by acting upon MT2 receptors. Chronobiol Int 29: 415–429.
144. Pinato L, da Silveira Cruz-Machado S, Franco DG, Campos LM, Cecon E, Fernandes PA et al. (2015). Selective protection of the cerebellum against intracerebroventricular LPS is mediated by local melatonin synthesis. Brain Struct Funct 220: 827–840.
145. Pires-Lapa MA, Tamura EK, Salustiano EM, Markus RP (2013). Melatonin synthesis in human colostrum mononuclear cells enhances dectin-1-mediated phagocytosis by mononuclear cells. J Pineal Res 55: 240–246.
146. Poissonnier-Durieux S, Ettaoussi M, Peres B, Boutin JA, Audinot V, Bennejean C et al. (2008). Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands. Bioorg Med Chem 16: 8339–8348.
147. Pontes GN, Cardoso EC, Carneiro-Sampaio MM, Markus RP (2007). Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppresses nocturnal melatonin production. J Pineal Res 43: 365–371.
148. Prada C, Udin SB, Wiechmann AF, Zhdanova IV (2005). Stimulation of melatonin receptors decreases calcium levels in xenopus tectal cells by activating GABA(C) receptors. J Neurophysiol 94: 968–978.
149. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G et al. (2009). Variants in MTNR1B influence fasting glucose levels. Nat Genet 41: 77–81.
150. Provasi D, Artacho MC, Negri A, Mobarec JC, Filizola M (2011). Ligand-induced modulation of the free-energy landscape of G protein-coupled receptors explored by adaptive biasing techniques. PLoS Comput Biol 7: e1002193.
151. Racagni G, Riva MA, Molteni R, Musazzi L, Calabrese F, Popoli M et al. (2011). Mode of action of agomelatine: Synergy between melatonergic and 5-HT(2C) receptors. World J Biol Psychiatry 12: 574–587.
152. Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G et al. (2009). Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 373: 482–491.
153. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS et al. (2011a). Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469: 175–180.
154. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS et al. (2011b). Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477: 549–555.
155. Rawashdeh O, Hudson RL, Stepien I, Dubocovich ML (2011). Circadian periods of sensitivity for ramelteon on the onset of running-wheel activity and the peak of suprachiasmatic nucleus neuronal firing rhythms in C3H/HeN mice. Chronobiol Int 28: 31–38.
156. Ressmeyer AR, Mayo JC, Zelosko V, Sainz RM, Tan DX, Poeggeler B et al. (2003). Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep 8: 205–213.
157. Rivara S, Lodola A, Mor M, Bedini A, Spadoni G, Lucini V et al. (2007). N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem 50: 6618–6626.
158. Rivara S, Lorenzi S, Mor M, Plazzi PV, Spadoni G, Bedini A et al. (2005). Analysis of structure–activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models. J Med Chem 48: 4049–4060.
159. Rivara S, Pala D, Lodola A, Mor M, Lucini V, Dugnani S et al. (2012). MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides. ChemMedChem 7: 1954–1964.
160. Rosen R, Hu DN, Perez V, Tai K, Yu GP, Chen M et al. (2009). Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients. Mol Vis 15: 1673–1679.
161. Sampaio Lde F, Mesquita FP, de Sousa PR, Silva JL, Alves CN (2014). The melatonin analog 5-MCA-NAT increases endogenous dopamine levels by binding NRH:quinone reductase enzyme in the developing chick retina. Int J Dev Neurosci 38: 119–126.
162. Savaskan E, Olivieri G, Meier F, Brydon L, Jockers R, Ravid R et al. (2002). Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res 32: 59–62.
163. Savaskan E, Schnitzler C, Schroder C, Cajochen C, Muller-Spahn F, Wirz-Justice A (2006). Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine. Int J Neuropsychopharmacol 9: 507–516.
164. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW et al. (2008). Crystal structure of opsin in its G-protein-interacting conformation. Nature 455: 497–502.
165. Sengupta A, Baba K, Mazzoni F, Pozdeyev NV, Strettoi E, Iuvone PM et al. (2011). Localization of melatonin receptor 1 in mouse retina and its role in the circadian regulation of the electroretinogram and dopamine levels. PLoS One 6: e24483.
166. Sharma S, Haldar C (2006). Melatonin prevents X-ray irradiation induced oxidative damagein peripheral blood and spleen of the seasonally breeding rodent, Funambulus pennanti during reproductively active phase. Int J Radiat Biol 82: 411–419.
167. Sheynzon P, Korf HW (2006). Targeted deletions of Mel1a and Mel1b melatonin receptors affect pCREB levels in lactotroph and pars intermedia cells of mice. Neurosci Lett 407: 48–52.
168. Shin IS, Shin NR, Park JW, Jeon CM, Hong JM, Kwon OK et al. (2015). Melatonin attenuates neutrophil inflammation and mucus secretion in cigarette smoke-induced chronic obstructive pulmonary diseases via the suppression of Erk-Sp1 signaling. J Pineal Res 58: 50–60.
169. Soundararajan M, Willard FS, Kimple AJ, Turnbull AP, Ball LJ, Schoch GA et al. (2008). Structural diversity in the RGS domain and its interaction with heterotrimeric G protein alpha-subunits. Proc Natl Acad Sci U S A 105: 6457–6462.
170. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44 (Database Issue): D1054–D1068.
171. Spadoni G, Bedini A, Lucarini S, Mari M, Caignard DH, Boutin JA et al. (2015). Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines. J Med Chem 58: 7512–7525.
172. Spadoni G, Bedini A, Orlando P, Lucarini S, Tarzia G, Mor M et al. (2011). Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide: synthesis, binding affinity and intrinsic activity for MT(1) and MT(2) melatonin receptors. Bioorg Med Chem 19: 4910–4916.
173. Stumpf I, Muhlbauer E, Peschke E (2008). Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic beta-cells. J Pineal Res 45: 318–327.
174. Sugden D, Chong NW, Lewis DF (1995). Structural requirements at the melatonin receptor. Br J Pharmacol 114: 618–623.
175. Sugden D, Yeh LK, Teh MT (1999). Design of subtype selective melatonin receptor agonists and antagonists. Reprod Nutr Dev 39: 335–344.
176. Tamura EK, Fernandes PA, Marcola M, da Silveira Cruz-Machado S, Markus RP (2010). Long-lasting priming of endothelial cells by plasma melatonin levels. PLoS One 5: e13958.
177. Tan DX, Manchester LC, Esteban-Zubero E, Zhou Z, Reiter RJ (2015). Melatonin as a Potent and Inducible Endogenous Antioxidant: Synthesis and Metabolism. Molecules 20: 18886–18906.
178. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ (2007). One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 42: 28–42.
179. Tchekalarova J, Nenchovska Z, Atanasova D, Atanasova M, Kortenska L, Stefanova M et al. (2016). Consequences of long-term treatment with agomelatine on depressive-like behavior and neurobiological abnormalities in pinealectomized rats. Behav Brain Res 302: 11–28.
180. Tosini G, Baba K, Hwang CK, Iuvone PM (2012). Melatonin: an underappreciated player in retinal physiology and pathophysiology. Exp Eye Res 103: 82–89.
181. Tosini G, Owino S, Guillaume JL, Jockers R (2014). Understanding melatonin receptor pharmacology: Latest insights from mouse models, and their relevance to human disease. Bioessays 36: 778–787.
182. Uchikawa O, Fukatsu K, Tokunoh R, Kawada M, Matsumoto K, Imai Y et al. (2002). Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J Med Chem 45: 4222–4239.
183. Vakkuri O, Leppaluoto J, Vuolteenaho O (1984). Development and validation of a melatonin radioimmunoassay using radioiodinated melatonin as a tracer. Acta Endocrinol 106: 152–157.
184. van Wamelen DJ, Aziz NA, Anink JJ, van Steenhoven R, Angeloni D, Fraschini F et al. (2013). Suprachiasmatic nucleus neuropeptide expression in patients with Huntington's Disease. Sleep 36: 117–125.
185. van Wamelen DJ, Roos RA, Aziz NA (2015). Therapeutic strategies for circadian rhythm and sleep disturbances in Huntington disease. Neurodegener Dis Manag 5: 549–559.
186. Vanecek J (1988). Melatonin binding sites. J Neurochem 51: 1436–1440.
187. Vincent L, Cohen W, Delagrange P, Boutin JA, Nosjean O (2010). Molecular and cellular pharmacological properties of 5-methoxycarbonylamino-N-acetyltryptamine (MCA-NAT): a nonspecific MT3 ligand. J Pineal Res 48: 222–229.
188. von Gall C, Garabette ML, Kell CA, Frenzel S, Dehghani F, Schumm DP et al. (2002). Rhythmic gene expression in pituitary depends on heterologous sensitization by the neurohormone melatonin. Nat Neurosci 5: 234–238.
189. Voronkov AE, Ivanov AA, Baskin II, Palyulin VA, Zefirov NS (2005). Molecular modeling study of the mechanism of ligand binding to human melatonin receptors. Dokl Biochem Biophys 403: 284–288.
190. Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T et al. (2014). Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging 9: 947–961.
191. Wang LM, Suthana NA, Chaudhury D, Weaver DR, Colwell CS (2005). Melatonin inhibits hippocampal long-term potentiation. Eur J Neurosci 22: 2231–2237.
192. Wang X, Sirianni A, Pei Z, Cormier K, Smith K, Jiang J et al. (2011). The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J Neurosci 31: 14496–14507.
193. Weil ZM, Borniger JC, Cisse YM, Abi Salloum BA, Nelson RJ (2015). Neuroendocrine control of photoperiodic changes in immune function. Front Neuroendocrinol 37: 108–118.
194. Weishaupt JH, Bartels C, Polking E, Dietrich J, Rohde G, Poeggeler B et al. (2006). Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 41: 313–323.
195. Wu YH, Zhou JN, Van Heerikhuize J, Jockers R, Swaab DF (2007). Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Neurobiol Aging 28: 1239–1247.
196. Yadav SK, Haldar C (2013). Reciprocal interaction between melatonin receptors (Mel(1a), Mel(1b), and Mel(1c)) and androgen receptor (AR) expression in immunoregulation of a seasonally breeding bird, Perdicula asiatica: role of photoperiod. J Photochem Photobiol B 122: 52–60.
197. Yasuo S, Yoshimura T, Ebihara S, Korf HW (2009). Melatonin transmits photoperiodic signals through the MT1 melatonin receptor. J Neurosci 29: 2885–2889.
198. Zavala-Oseguera C, Galano A, Merino G (2014). Computational study on the kinetics and mechanism of the carbaryl + OH reaction. J Phys Chem A 118: 7776–7781.
199. Zefirova ON, Baranova TY, Ivanova AA, Ivanov AA, Zefirov NS (2011). Application of the bridgehead fragments for the design of conformationally restricted melatonin analogues. Bioorg Chem 39: 67–72.
200. Zhang W, Chen XY, Su SW, Jia QZ, Ding T, Zhu ZN et al. (2016). Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol Sci 37: 57–65.
201. Zhang Y, Cook A, Kim J, Baranov SV, Jiang J, Smith K et al. (2013). Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 55: 26–35.
202. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF (2003). Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 35: 125–130.
203. Zisapel N, Egozi Y, Laudon M (1985). Circadian variations in the inhibition of dopamine release from adult and newborn rat hypothalamus by melatonin. Neuroendocrinology 40: 102–108.
204. Zisapel N, Laudon M (1982). Dopamine release induced by electrical field stimulation of rat hypothalamus in vitro: inhibition by melatonin. Biochem Biophys Res Commun 104: 1610–1616.
205. Zlotos DP (2012). Recent progress in the development of agonists and antagonists for melatonin receptors. Curr Med Chem 19: 3532–3549.
206. Zlotos DP, Attia MI, Julius J, Sethi S, Witt-Enderby PA (2009). 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem 52: 826–833.
207. Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA (2014). MT1 and MT2 Melatonin Receptors: Ligands, Models, Oligomers, and Therapeutic Potential. J Med Chem 57: 3161–3185.
208. Zlotos DP, Riad NM, Osman MB, Dodda BR, Witt-Enderby PA (2015). Novel difluoroacetamide analogues of agomelatine and melatonin: probing the melatonin receptors for MT1 selectivity. Med Chem Commun 6: 1340–1344.